<DOC>
	<DOCNO>NCT01067131</DOCNO>
	<brief_summary>Pevion Biotech develop state-of-the-art vaccine recurrent vulvovaginal candidiasis ( RVVC ) cause pathogenic form Candida albicans especially pre-menopausal woman childbearing age history recurrent vulvovaginal candidiasis . This study design evaluate safety tolerability vaccine , administer two different route ( intramuscular intravaginal ) primary endpoint . Immunogenicity evaluate secondary endpoint .</brief_summary>
	<brief_title>Safety Immunogenicity Study Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Vulvovaginal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Females age 18 45 year . Written inform consent obtain volunteer . Free obvious health problem establish medical history and/or clinical examination and/or gynecological examination enter study . Body Mass Index 18.0 30.0 . A negative pregnancy test adequate contraception least 4 week last vaccination primary vaccination course . Adequate contraception mean use physicianprescribed oral hormonal agent AND use condom ( without spermicidal agent ) time . Progesteroneonly contraceptives suitable due lack regular menstrual cycle . Availability duration study willingness attend schedule visit . No vaginal practice receptive intercourse male use sanitary tampon menses . Negative culture Candida species visit 2 . Subjects positive culture treat Candida culture repeat . They eligible negative culture result available prior visit 2 ( first vaccination ) . Known suspect history cervicovaginal malignancy abnormality discover time screening . Ovarectomised hysterectomised woman exclude study . Presence Chlamydia trachomatis , Neisseria gonorrhoeae infection detect PCR screen visit . Presence bacterial vaginosis ( assessed Amsel criterion bacterial culture ) group 1 2 screening visit ; day 0±2 , 28±2 56±2 , group 3 4 screen Amsel criterion day 0±2 28±2 . Use investigational nonregistered drug vaccine within 30 day precede first dose study vaccine , plan use study period safety followup . Planned use register vaccine study vaccine plan use immunoglobulinbased therapy immunization phase 14 day last immunization ( Day 0 day 70 group 1 2 ; Day 0 Day 56 group 3 4 ) group 1 2 application booster vaccine dose 14 day administration . Receipt live attenuate vaccine within 30 day prior first vaccination 30 day last vaccination immunization period . Equally apply period 30 day prior 30 day booster vaccination . Any therapy medication via vaginal route 7 day prior first vaccination period first dose study vaccine last safety visit ( Groups 1 2 : Day 140±2 ; Groups 3 4 : Day 70±2 ) . Equally applies period 7 day prior booster vaccination end study ( Groups 1 2 ) . Chronic administration ( define 14 consecutive day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . ( For corticosteroid , mean prednisone , equivalent , &gt; 0.5 mg/kg/day . Inhaled topical steroid allow . ) Samples obtain screen visit show : 1. clinically significant amount protein and/or haemoglobin urine sample 2. clinically significant abnormality haematological biochemicals assay 3. positive antibody assay Hepatitis B and/or C and/or HIV Any chronic drug therapy continue study period ( except oral hormonal contraceptive ) Any confirm suspected acquire immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection , history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine component use manufacturing process vaccine like egg chick protein . Acute disease time enrollment . { Acute disease define presence moderate severe illness without fever . All vaccine administer person minor illness diarrhea , mild upper respiratory infection without lowgrade febrile illness , i.e. , temperature &lt; 38°C ( &lt; 100.4°F ) } . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , blood disorder immune dysfunction determine physical examination laboratory screen test . Acute chronic diabetes . History chronic alcohol consumption and/or intravenous drug abuse . Pregnancy lactation . Subject plan become pregnant .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Candida albicans</keyword>
	<keyword>Fungal vaginal infection</keyword>
	<keyword>Vulvovaginal candidiasis</keyword>
	<keyword>Candidose</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Virosome</keyword>
</DOC>